Abstract: The present invention includes compositions and method of generating human corneal epithelial stem cells, a human corneal epithelial stem cell supernatant, or both, the method comprising: wetting and mincing a corneal epithelial sample in a media, drying the minced corneal epithelial sample until sample edges are adhered to a substrate, adding a growth media comprising fetal bovine serum or human serum to the minced corneal epithelial sample without dislodging the minced corneal epithelial sample from the substrate with an amount of media that permits at least a portion of the minced corneal epithelial sample to be in contact with air, culturing the minced corneal epithelial sample for one or more days, changing the growth media to a media comprising a human corneal growth supplement (HCGS) with no fetal bovine serum, culturing the cells to grow human corneal epithelial stem cells, a human corneal epithelial stem cell supernatant, or both.

Abstract: The present invention includes compositions and methods comprising: a cancer antigen-specific chimeric antigen receptor cells, e.g., alpha-beta cell receptor T cells, gamma delta cell receptor T cells, induced pluripotent stem cells, hematopoietic stem cells, or natural killer (NK) cells or gamma delta cell receptor T cells, genetically engineered to express non-released IL-12, anchored IL-12, and/or cleavage-resistant IL-12 only, transfected with one or more costimulatory genes; and one or more immune modulators, regulated for safety, in an amount sufficient to eliminate the effect of at least one of myeloid derived suppressor cells (MDSC) or Tregs on the cells or CAR-T cells and eliminate cancer cells.

Abstract: The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

Abstract: The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.